logo.png
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
19 juil. 2024 08h01 HE | Silo Pharma, Inc.
SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
clearmindlogo.png
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
19 juil. 2024 07h55 HE | Clearmind Medicine Inc.
Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
BitFuFu Inc. to Participate in the Bitcoin 2024 Conference
18 juil. 2024 05h00 HE | Bitfufu Inc.
SINGAPORE, July 18, 2024 (GLOBE NEWSWIRE) -- BitFuFu Inc., (“BitFuFu” or “the Company”) (NASDAQ: FUFU), a fast-growing digital asset mining service and world-leading cloud-mining service provider,...
946458CD-EBDF-4EA1-9428-F2B64327B8CD.jpg
TIAN RUIXIANG Holdings Ltd Reports Financial Results for Fiscal Year Ended October 31, 2023
17 juil. 2024 17h42 HE | Tian Ruixiang Holdings Ltd.
BEIJING, July 17, 2024 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company"), a China-based insurance broker conducting business through its variable interest entity in...
scilogo.jpg
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
17 juil. 2024 07h07 HE | SciSparc Ltd
SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
canfite_logo.jpg
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
17 juil. 2024 07h00 HE | Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
clearmindlogo.png
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
16 juil. 2024 09h02 HE | Clearmind Medicine Inc.
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
wd_logo.jpg
Wearable Devices Unveils the Revolutionary Mudra LINK: The First AI Neural Interface Wristband for Android and Beyond
16 juil. 2024 08h45 HE | Wearable Devices Ltd.
YOKNEAM ILLIT, ISRAEL, July 16, 2024 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial...
scilogo.jpg
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
16 juil. 2024 06h03 HE | SciSparc Ltd
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
11 juil. 2024 07h00 HE | Can-Fite BioPharma Ltd.
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...